These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 36170295)
1. Mutations of tyrosine 467 in the human norepinephrine transporter attenuate HIV-1 Tat-induced inhibition of dopamine transport while retaining physiological function. Strauss MJ; Porter KD; Quizon PM; Davis SE; Lin S; Yuan Y; Martinez-Muniz GA; Sun WL; Zhan CG; Zhu J PLoS One; 2022; 17(9):e0275182. PubMed ID: 36170295 [TBL] [Abstract][Full Text] [Related]
2. Effects of SRI-32743, a Novel Quinazoline Structure-Based Compound, on HIV-1 Tat and Cocaine Interaction with Norepinephrine Transporter. Jiménez-Torres AC; Porter KD; Hastie JA; Adeniran C; Moukha-Chafiq O; Nguyen TH; Ananthan S; Augelli-Szafran CE; Zhan CG; Zhu J Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063123 [TBL] [Abstract][Full Text] [Related]
3. Mutations at tyrosine 88, lysine 92 and tyrosine 470 of human dopamine transporter result in an attenuation of HIV-1 Tat-induced inhibition of dopamine transport. Midde NM; Yuan Y; Quizon PM; Sun WL; Huang X; Zhan CG; Zhu J J Neuroimmune Pharmacol; 2015 Mar; 10(1):122-35. PubMed ID: 25604666 [TBL] [Abstract][Full Text] [Related]
4. Mutations of Human DopamineTransporter at Tyrosine88, Aspartic Acid206, and Histidine547 Influence Basal and HIV-1 Tat-inhibited Dopamine Transport. Quizon PM; Yuan Y; Zhu Y; Zhou Y; Strauss MJ; Sun WL; Zhan CG; Zhu J J Neuroimmune Pharmacol; 2021 Dec; 16(4):854-869. PubMed ID: 33537927 [TBL] [Abstract][Full Text] [Related]
5. Mutation of tyrosine 470 of human dopamine transporter is critical for HIV-1 Tat-induced inhibition of dopamine transport and transporter conformational transitions. Midde NM; Huang X; Gomez AM; Booze RM; Zhan CG; Zhu J J Neuroimmune Pharmacol; 2013 Sep; 8(4):975-87. PubMed ID: 23645138 [TBL] [Abstract][Full Text] [Related]
6. Site-directed mutations near transmembrane domain 1 alter conformation and function of norepinephrine and dopamine transporters. Guptaroy B; Fraser R; Desai A; Zhang M; Gnegy ME Mol Pharmacol; 2011 Mar; 79(3):520-32. PubMed ID: 21149640 [TBL] [Abstract][Full Text] [Related]
7. Characteristics of drug interactions with recombinant biogenic amine transporters expressed in the same cell type. Eshleman AJ; Carmolli M; Cumbay M; Martens CR; Neve KA; Janowsky A J Pharmacol Exp Ther; 1999 May; 289(2):877-85. PubMed ID: 10215666 [TBL] [Abstract][Full Text] [Related]
8. Tyrosine residue 271 of the norepinephrine transporter is an important determinant of its pharmacology. Paczkowski FA; Bryan-Lluka LJ Brain Res Mol Brain Res; 2001 Dec; 97(1):32-42. PubMed ID: 11744160 [TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism: the human dopamine transporter histidine 547 regulates basal and HIV-1 Tat protein-inhibited dopamine transport. Quizon PM; Sun WL; Yuan Y; Midde NM; Zhan CG; Zhu J Sci Rep; 2016 Dec; 6():39048. PubMed ID: 27966610 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological properties of the naturally occurring Ala(457)Pro variant of the human norepinephrine transporter. Paczkowski FA; Bönisch H; Bryan-Lluka LJ Pharmacogenetics; 2002 Mar; 12(2):165-73. PubMed ID: 11875370 [TBL] [Abstract][Full Text] [Related]
11. Binding Mode of Human Norepinephrine Transporter Interacting with HIV-1 Tat. Adeniran C; Yuan Y; Davis SE; Lin C; Xu J; Zhu J; Zhan CG ACS Chem Neurosci; 2021 May; 12(9):1519-1527. PubMed ID: 33886267 [TBL] [Abstract][Full Text] [Related]
12. Mutational effects of human dopamine transporter at tyrosine88, lysine92, and histidine547 on basal and HIV-1 Tat-inhibited dopamine transport. Sun WL; Quizon PM; Yuan Y; Strauss MJ; McCain R; Zhan CG; Zhu J Sci Rep; 2019 Mar; 9(1):3843. PubMed ID: 30846720 [TBL] [Abstract][Full Text] [Related]
13. SRI-32743, a novel allosteric modulator, attenuates HIV-1 Tat protein-induced inhibition of the dopamine transporter and alleviates the potentiation of cocaine reward in HIV-1 Tat transgenic mice. Zhu J; Quizon PM; Wang Y; Adeniran CA; Strauss MJ; Jiménez-Torres AC; Patel P; Cirino TJ; Eans SO; Hammond HR; Deliscar LS; O'Hara P; Saini SK; Ofori E; Vekariya RH; Zhang S; Moukha-Chafiq O; Nguyen TH; Ananthan S; Augelli-Szafran CE; Zhan CG; McLaughlin JP Neuropharmacology; 2022 Dec; 220():109239. PubMed ID: 36126727 [TBL] [Abstract][Full Text] [Related]
14. Dopamine and norepinephrine transporter-dependent c-Fos production in vitro: relevance to neuroadaptation. Yatin SM; Miller GM; Madras BK J Neurosci Methods; 2005 Apr; 143(1):69-78. PubMed ID: 15763138 [TBL] [Abstract][Full Text] [Related]
15. Role of Histidine 547 of Human Dopamine Transporter in Molecular Interaction with HIV-1 Tat and Dopamine Uptake. Yuan Y; Quizon PM; Sun WL; Yao J; Zhu J; Zhan CG Sci Rep; 2016 Jun; 6():27314. PubMed ID: 27250920 [TBL] [Abstract][Full Text] [Related]
16. Allosteric modulatory effects of SRI-20041 and SRI-30827 on cocaine and HIV-1 Tat protein binding to human dopamine transporter. Sun WL; Quizon PM; Yuan Y; Zhang W; Ananthan S; Zhan CG; Zhu J Sci Rep; 2017 Jun; 7(1):3694. PubMed ID: 28623359 [TBL] [Abstract][Full Text] [Related]
18. Down-regulation of the human norepinephrine transporter in intact 293-hNET cells exposed to desipramine. Zhu MY; Blakely RD; Apparsundaram S; Ordway GA J Neurochem; 1998 Apr; 70(4):1547-55. PubMed ID: 9523572 [TBL] [Abstract][Full Text] [Related]
19. Involvement of the NH2 terminal domain of catecholamine transporters in the Na(2+) and Cl(-)-dependence of a [3H]-dopamine uptake. Syringas M; Janin F; Giros B; Costentin J; Bonnet JJ Br J Pharmacol; 2001 Jun; 133(3):387-94. PubMed ID: 11375255 [TBL] [Abstract][Full Text] [Related]
20. The role of cysteines and histidins of the norepinephrine transporter. Wenge B; Bönisch H Neurochem Res; 2013 Jul; 38(7):1303-14. PubMed ID: 23525969 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]